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and accessing the best available evidence to address a given research question. Our 
objective was to develop a systematic methodology to identify observational data 
sources for specific needs and to test it in both common and rare conditions in a 
range of therapeutic areas. Methods: Systematic literature and Web searches, 
supplemented with email and telephone contact with data owners, were used to 
identify and characterize data sources suitable for use in 6 observational research 
programs spanning oncology, cardiology, and respiratory medicine. Data were cap-
tured and project-specific evaluation criteria applied regarding: study population; 
target geographies; type of clinical, diagnostic, and health care data required; length 
of follow up; and ability to identify patients across data sources. Data sources best 
meeting program objectives were recommended. Results: Over 14,000 references 
were screened across 6 separate studies. Of these, 4.5% to 8.6% were relevant to each 
study and were reviewed further. Direct contact with data owners was often needed 
to clarify whether inpatient and outpatient drug utilization, laboratory and imaging 
results, clinical assessments, health care utilization, patient-reported outcomes, 
and mortality data were available. Detailed characterization of the data sources 
identified by the systematic search reduced their number by 150–300-fold. This 
generated a manageable number of data sources (4–17 per study) to address specific 
research questions, including for prevalent cardiac conditions as well as a rare 
respiratory sub-population, in target geographies. ConClusions: The approach 
was effective in identifying accessible, relevant, and high-quality data for both rare 
and more prevalent conditions. A systematic understanding of real-world evidence 
has helped to guide observational research programs in diverse therapeutic areas 
with specialized data requirements.
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objeCtives: With the explosion of medical data, it is necessary to develop software 
tools to support the process of evidence review and synthesis that is fundamental to 
Evidence-Based Medicine. Furthermore, as predictive models are being increasingly 
integrated into clinical decision making for individual patients, there is an even 
greater need for a practical tool that enables development, validation, and uncer-
tainty quantification of models in a robust, automatic and efficient way. Methods: 
We developed Evidence Synthesis Engine (ESE), a software platform that enables 
users to display, compare and synthesize evidence from multiple data sources, to 
estimate disease risks, to validate risk models, to build predictive models, to rec-
alibrate existing models as new data becomes available, to evaluate improvement 
in prediction performance between two models, and to quantify the accuracy of 
a predictive model in different subpopulations. Results: We applied ESE to data 
from eight cardiovascular studies (six cohort studies and two clinical trials) with 
a total size of over 147,000 participants. ESE allows users to create customized 
pooled cohorts and subpopulations from these data sources. Users can assess the 
performance of predictive models for different subpopulations in real time. Several 
metrics were used for model evaluation: cumulative incidence, calibration plots, 
receiver operating curve and net reclassification index. ESE also allows users to 
generate and then assess models for risks of MI, stroke, heart failure, coronary 
death or composite cardiovascular outcome for a predefined subpopulation from 
selected datasets. We used ESE to evaluate the performance of five cardiovascular 
risk equations. The results suggested that compared to four other well-accepted 
cardiovascular risk equations, the 2013 Pooled Cohort Equations for 10-year risk of 
ASCVD could have superior performance for the individuals considered in these 
eight studies. ConClusions: ESE proves to be a useful tool for advancing the devel-
opment and application of predictive modeling in medicine.
PRM50
the APPlicAtion of big dAtA AnAlytics And high PeRfoRMAnce 
coMPuting to deliveR instAnt insight on longitudinAl diseAse 
MAnAgeMent
Khosla S.
AstraZeneca, Macclesfield, UK
objeCtives: The abundance and availability of health care data has risen expo-
nentially in recent time, coming from a variety of health systems. These data have 
the ability to provide rich insight into the outcomes of care, standards of care and 
specifically the descriptive patterns of treatments. However the barrier to this rich 
insight is twofold; technical and methodological. This methods piece will demon-
strate how the application of high performance computing technology has been 
able to erode technical and methodological boundaries to these data and provide 
fresh insight in to the chronic disease management within longitudinal patient 
records. Methods: Data from MarketScan, Clinical Practice Research Database 
(CPRD), IMS-Health and the Hospital Episodes Statistics (HSCIC) have been loaded 
into a High performance computing centre, hosting > 100 Million patient lives with 
> 15 years of linked longitudinal data. Algorithms to define treatment & diagnostic 
exposures/duration and procedural observations, defined with specific structure 
query languages. These views feed a visual analytics interface of prevalence/inci-
dence/demographic breakdown/patient interactions and specifically patient path-
ways. Results: The combination of standardised visual analytics interfaces on 
these health care data highlight nuances and intricacies in longitudinal patient 
pathways and records. These automated technologies enable the researchers to 
instantaneously assess and triangulate trends of disease presentation, treatment 
and laboratory assessments. We highlight the use of these tools to assess factors 
used in a Bayesian modelling exercise to assess fluctuations of a laboratory result 
recorded over time on the prediction of a rare event. ConClusions: Generation and 
analytics of disease cohorts and from high dimensional datasets requires careful 
longitudinal interrogation of factors prior to analysis. This factor analysis is often 
missed in the creation of disease segments and often leads to misinterpretation of 
data. The use of visual analytics tools combined with high performance comput-
to each patient using the Marketscan National Weights for 2011. Estimates of the ESI 
population were calculated by summing the weights across the study population. 
The same approach was used for patients with a condition or measure of interest. 
A modified “precision rounding” approach was applied to subpopulation estimates 
to ensure that the sum each sub-category estimate would add to the total popula-
tion. Results: We estimated a total population of 160,714,971 with EIS in 2011. Of 
those, 0.7% had COPD, 2.4% had Asthma, and 5% had Diabetes. A total of 5.9% of 
COPD patients had a level 2 or 3 exacerbation and 31.4% of newly diagnosed patients 
received spirometry testing. For Asthma patients, 13.6% had 2+ oral steroid fills, and 
2.5% had 4+ SABA fills within a period of 90 days. For Diabetes patients 50% had 
2+ HbA1c tests, 25% had an eye exam, and 70.4% had an LDL test. ConClusions: 
With the burden of chronic diseases remaining a significant source of health care 
costs, the ability to estimate national prevalence and projection estimates obtained 
from claims data provide an excellent source of information to benchmark quality 
of care in the hope of improving quality of life for patients.
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objeCtives: Created in 2002, the Patient-Reported Outcome and Quality of Life 
Instruments database (PROQOLID) provides a detailed description of 773 generic, 
disease-, and population-specific Patient-Centered Outcomes measures on the 
Internet (www.proqolid.org). The objective of this study was to find out if PROQOLID 
could help researchers identify questionnaires available in French for use in 
Quebec. Methods: The PROQOLID database was explored on November 10, 2013 
using the search engine and selecting in the language field the key words “French 
for Canada.” Results: Two hundred and twelve questionnaires were identified 
representing 27.42% of the instruments available in PROQOLID [in comparison, 383 
questionnaires (49.54%) were available in French for France]. Out of these 212 ques-
tionnaires, 26 were generic. Twenty different therapeutic areas were identified (e.g., 
endocrine system diseases, neoplasms, nervous system diseases, respiratory tract 
diseases, or psychiatric disorders), representing 75 different indications, and 83.33% 
of the therapeutic areas included in PROQOLID (n= 24). Twenty-three questionnaires 
were available for pediatric use (children and/or adolescents), either generic [e.g., 
Pediatric Quality of Life Inventory Generic Core (PedsQL)], or disease-specific [e.g., 
Paediatric Asthma Quality of Life Questionnaire (PAQLQ)]. Asthma and diabetes 
mellitus were the most frequent indications (16 questionnaires available for each 
indication), followed by dementia (including Alzheimer’s disease) and dyspepsia 
(eight questionnaires for each indication), pain (seven questionnaires), and sleep 
disorders (six questionnaires). Within the therapeutic area of neoplasms, five differ-
ent indications were identified (brain, breast, lung, myeloma and ovary), and seven 
questionnaires for generic use [e.g., EORTC Quality of Life Questionnaire – Core 
Questionnaire (EORTC QLQ-C30), Functional Living Index – Cancer (FLIC)]. Not a 
single instrument was identified in therapeutic areas such as bacterial infections 
and mycoses; congenital, hereditary diseases; stomatognathic diseases; and surgical 
procedures. ConClusions: This overview showed that Patient-Centered Outcome 
measures available for use in Quebec cover a wide variety of indications.
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objeCtives: Monitoring patient care outcomes is essential to ensure quality of 
care, hospital performance assessment and identification of areas of deficiency and 
for evaluation of strategies designed to overcome those weaknesses. We aimed to 
assess the impact of clinical database development on quality of care in the area of 
Paediatrics and Congenital Cardiac Surgery. Methods: The Cardiothoracic surgery 
division at the Aga Khan University Hospital maintains a computerized database 
of all the patients undergoing cardiac surgery since July 2006. For this study, data 
of 1236 patients operated between July 2006 and Sep 2013 was analyzed. Major 
measures of outcomes included in-hospital and 30 day mortality and morbidity 
outcomes like reopening, sepsis prolong ventilation, arrhythmias low cardiac output 
syndrome. Results: Out of a total of 1236 heart surgeries, the most common open 
heart surgeries were VSD 27%, TOF 24% were, and 13% were ASD. In closed heart 51% 
were Modified BT shunts, 17% were PDA. The overall 30-day mortality in open heart 
was 7.0%, and in closed heart it was 7.3%. Post-surgery more common complication 
in open heart surgery was prolong ventilation which was 39%,arrhythmias 14%,reo-
penings 11% and sepsis 5%total morbidity was 29% while in closed heart most com-
mon complication was prolong ventilation which was 31%, total morbidity was 21%. 
Readmissions after 30 day of Discharge were 8.4% mainly for respiratory infection. 
Followed with 85% patients were alive, 0.6% were died at 30 day patients follow up 
changes TOF;early extubation and improving survival. VSD: on table extubation or 
extubation with 4 hours – minimal morbidity and early discharges. ASD: on table 
extubation. ConClusions: Updated and stringently maintained database helped 
to identify deficiencies, strength and trends at our hospital and also to design strate-
gies for continuing improvement in patient care. Also provides scientific evidence 
for comparing results with other institutions of the region and world.
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objeCtives: Real-world evidence informs product development, pricing, and reim-
bursement as well as patient care. An ongoing challenge, however, is in identifying 
